MREO

Mereo BioPharma Group plc (MREO) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Profitability

Margins remain effectively zero, with TTM gross, operating, EBITDA, pretax, and net profit margins all at 0.0.

Returns are still deeply negative, including ROA of -0.81, ROE of -0.75, and ROIC of -1.13.

Growth

Fresh metrics do not show revenue or earnings growth support, with revenue per share still at 0 and profitability remaining negative.

No recent news indicates a new commercial catalyst or demand inflection.

Financial Health

Liquidity remains strong with a current ratio of 5.88 and cash ratio of 5.31.

Balance-sheet leverage is low, with debt-to-equity at 0.036 and debt-to-assets at 0.030, though solvency and coverage metrics remain distorted by negative operating earnings.

Valuation

The company still screens as asset-backed rather than earnings-backed, with price-to-book at 1.75 and tangible book value per share near 0.18.

Negative earnings and cash flow keep traditional earnings and cash-flow multiples non-informative, limiting valuation confidence.

Momentum

No fresh news or operating data suggests a momentum improvement this month.

The business remains unprofitable, which continues to weigh on sentiment and share-price support.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mereo BioPharma Group plc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →